Abstract
Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Current Gene Therapy
Title: The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Volume: 1 Issue: 1
Author(s): J. S. Norris, M. L. Hyer, C. Voelkel-Johnson, S. L. Lowe, S. Rubinchik and J-Y. Dong
Affiliation:
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Abstract: Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Export Options
About this article
Cite this article as:
Norris S. J., Hyer L. M., Voelkel-Johnson C., Lowe L. S., Rubinchik S. and Dong J-Y., The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer, Current Gene Therapy 2001; 1 (1) . https://dx.doi.org/10.2174/1566523013348977
DOI https://dx.doi.org/10.2174/1566523013348977 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Editorial {Hot topic: QSPR Models for Computer-Aided Drug Design in Microbiology, Parasitology, and Pharmacology (Guest Editor: Humberto Gonzalez-Diaz)]
Current Computer-Aided Drug Design Antidepressant-Like Components of Hypericum perforatum Extracts: An Overview of Their Pharmacokinetics and Metabolism
Current Drug Metabolism Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry A Brief Survey on Computational Approaches to Reveal Drug and Disease Associations
Current Drug Discovery Technologies Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry The IGF-I Signaling Pathway
Current Pharmaceutical Design Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry QSAR Study and Design of Novel Organoselenium and α-Tocopherol Derivatives with Enhanced Chemotherapeutic Activity
Letters in Drug Design & Discovery Podocytes as Target of Vitamin D
Current Diabetes Reviews Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Toxicity of Magnetic Resonance Imaging Agents: Small Molecule and Nanoparticle
Current Topics in Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Guaraná a Caffeine-Rich Food Increases Oxaliplatin Sensitivity of Colorectal HT-29 Cells by Apoptosis Pathway Modulation
Anti-Cancer Agents in Medicinal Chemistry